Intellia Therapeutics, Inc.·4

Mar 3, 4:18 PM ET

Lebwohl David 4

4 · Intellia Therapeutics, Inc. · Filed Mar 3, 2026

Insider Transaction Report

Form 4
Period: 2026-03-01
Lebwohl David
EVP, Chief Medical Officer
Transactions
  • Award

    Common Stock

    [F1]
    2026-03-01+9,943131,192 total
  • Award

    Stock Option (right to buy)

    [F2]
    2026-03-01+14,20414,204 total
    Exercise: $13.78Exp: 2036-02-29Common Stock (14,204 underlying)
Footnotes (2)
  • [F1]Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
  • [F2]This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.
Signature
James Basta, attorney-in-fact|2026-03-03

Documents

1 file
  • 4
    ownership.xmlPrimary

    4